30 April 2010

Renal Replacement Therapy



Renal Replacement Therapy

* What is it?
* How does it work?
Where did it come from?
History of Pediatric Hemofiltration
Mechanisms of Action: Convection
* Hydrostatic pressure pushes solvent across a semi-permeable membrane
* Solute is carried along with solvent by a process known as “solvent drag”
* Membrane pore size limits molecular transfer
* Efficient at removal of larger molecules compared with diffusion
* Solvent moves up a concentration gradient
* Solute diffuses down an concentration gradient

Mechanisms of Action: Diffusion
Semi-permeable Membranes
o Urea
o Creatinine
o Uric acid
o Sodium
o Potassium
o Ionized calcium
o Phosphate
o Almost all drugs not bound to plasma proteins
* Allow easy transfer of solutes less than 100 Daltons
o Bicarbonate
o Interleukin-1
o Interleukin-6
o Endotoxin
o Vancomycin
o Heparin
o Pesticides
o Ammonia
* Sieving Coefficient
* Sieving Coefficient is “1” for molecules that easily pass through the membrane and “0” for those that do not
* Continuous hemofiltration membranes consist of relatively straight channels of ever-increasing diameter that offer little resistance to fluid flow
* Intermittent hemodialysis membranes contain long, tortuous inter-connecting channels that result in high resistance to fluid flow

How is it done?
* Peritoneal Dialysis
* Hemodialysis
* Hemofiltration
* The choice of which modality to use depends on
o Patient’s clinical status
o Resources available

Peritoneal Dialysis
* Fluid placed into peritoneal cavity by catheter
* Glucose provides solvent gradient for fluid removal from body
* Can vary concentration of electrolytes to control hyperkalemia
* Can remove urea and metabolic products
* Can be intermittent or continuously cycled
* Simple to set up & perform
* Easy to use in infants
* Hemodynamic stability
* No anti-coagulation
* Bedside peritoneal access
* Treat severe hypothermia or hyperthermia
* Unreliable ultrafiltration
* Slow fluid & solute removal
* Drainage failure & leakage
* Catheter obstruction
* Respiratory compromise
* Hyperglycemia
* Peritonitis
* Not good for hyperammonemia or intoxication with dialyzable poisons

Intermittent Hemodialysis
* Maximum solute clearance of 3 modalities
* Best therapy for severe hyperkalemia
* Limited anti-coagulation time
* Bedside vascular access can be used
* Hemodynamic instability
* Hypoxemia
* Rapid fluid and electrolyte shifts
* Complex equipment
* Specialized personnel
* Difficult in small infants

Continuous Hemofiltration
* Easy to use in PICU
* Rapid electrolyte correction
* Excellent solute clearances
* Rapid acid/base correction
* Controllable fluid balance
* Tolerated by unstable patients
* Early use of TPN
* Bedside vascular access routine
* Systemic anticoagulation (except citrate)
* Frequent filter clotting
* Vascular access in infants

SCUF:Slow Continuous Ultrafiltration
* Pros
* Cons
Continuous Venovenous Hemofiltration
Dialysis Fluid
Continuous Venovenous Hemodialysis
Continuous Venovenous Hemodialysis with Ultrafiltration
Is there a “Best” Method?
Indications for Renal Replacement Therapy
Indicators of Circuit Function
Filtration Fraction
QP: the filter plasma flow rate in ml/min
Blood Flow Rate & Clearance
Pediatric CRRT Vascular Access: Performance = Blood Flow!!!
Urea Clearance
Solute Molecular Weight and Clearance
Cytokines (large) adsorbed minimal clearance
Replacement Fluids
Physiologic Replacement Fluid
Anticoagulation
Mechanisms of Filter Thrombosis
Heparin - Problems
Sites of Action of Citrate
Anticoagulation: Citrate
What are the targets?
Unknowns of Hemofiltration for Sepsis
Pediatric CRRT in the PICU
Renal Replacement Therapy in the PICU Pediatric Literature

Renal Replacement Therapy.ppt

Read more...

Renal Replacement Therapy



Renal Replacement Therapy
Trauma Conference
By:Amanda Wheeler, MD

Principles
4 Main Modalities in ICU
* HD
* PD
* CVVH
* CVVHD

Definition of Terms
* SCUF- Slow Continuous Ultrafiltration
* CAVH- Continuous Arteriovenous Hemofiltration
* CAVH-D- Continuous Arteriovenous Hemofiltration with Dialysis
* CVVH- Continuous Venovenous Hemofiltration
* CVVH-D- Continuous Venovenous Hemofiltration with Dialysis

Indications for Continuous Renal Replacement Therapy
* Volume Overload
* Electrolyte Imbalance
* Uremia
* Acid-Base Disturbances
* Drugs

Hemodialysis vs Hemofiltration Membrane
The hemofiltration membrane consists of relatively straight channels of ever-increasing diameter that offer little resistance to fluid flow.
Hemodialysis membranes contain long, tortuous inter-connecting channels that result in high resistance to fluid flow.
Hemodialysis allows the removal of water and solutes by diffusion across a concentration gradient.

Hemodialysis
* maximum solute clearance
* best tx for severe hyper-K+
* ready availability
* limited anti-coagulation time
* bedside vascular access
* hemodynamic instability
* hypoxemia
* rapid fluid + solute shifts
* complex equipment
* specialized personnel

advantages
disadvantages

Peritoneal Dialysis
* simple to set up + perform
* easy to use
* hemodynamic stability
* no anti-coagulation
* bedside peritoneal access
* unreliable ultrafiltration
* slow fluid + solute removal
* drainage failure, leakage
* catheter obstruction
* respiratory compromise
* hyperglycemia
* peritonitis

advantages
disadvantages

CVVHD vs CVVH
CVVH
* 1. near-complete control of the rate of fluid removal (i.e. the ultrafiltration rate)
* 2. precision and stability
* 3. electrolytes or any formed element of the circulation, including platelets or red or white blood cells, can be removed or added independent of changes in the volume of total body water

CVVH
* easy to use in ICU
* rapid electrolyte correction
* excellent solute clearances
* rapid acid/base correction
* controllable fluid balance
* tolerated by unstable patients
* early use of TPN
* bedside vascular access routine
* systemic anticoagulation *
* citrate anticoagulation new
* frequent filter clotting
* hypotension

advantages
disadvantages

Renal Replacement Therapy.ppt

Read more...

29 April 2010

Bacteria Pathogenicity Ability to Cause Infection



Bacteria Pathogenicity Ability to Cause Infection

Infectious Diseases
* Encounter-bug meets host (reservoir)
* Bug adheres to host
* Entry-bug enters host
* Multiplication- bug multiplies in host
* Damage to host
* Outcome- bug or host wins or
* Coexist- chronic infection

Reservoir
* Exposure to microbe
Virulence Factors
Adherence
* Prevent infection
* Influenza changes adhesions over time
* Neisseria gonorrhoeae -variety of adhesions

Portals of Entry
* Mucous membranes
* Conjunctiva
* Skin
* Bugs have preferred portal
* C. tetani spores in soil --- anaerobic wound

Inoculum

* Number of microbes-dose
* Greater dose, more chance infection will occur
* ID50 or LD50 expresses virulence

Invasins
* Adherence of microbe to surface
* Activates factors that let microbe in-penetration
* Microbes produce invasins (proteins)
* Endocytosis
* Requires multiplication
* Compete with normal flora for space & nutrients
* Overcome local host defenses
* Avoid IgA

Multiplication
* Need Fe to multiply
Avoid Phagocytosis
* Components of cell wall –virulence
Surviving Within Phagocyte

Tuberculosis
* Ancient disease
* 1/3 of world population infected
* 8 million develop active TB each year
* 2 million die each year
* AIDs increases activation of latent TB
* Dependent upon virulence of strain & host resistance
* Produces cell mediated immunity which prevents active disease in many people
* Multi drug resistance has developed

S & S of Pulmonary TB
* Chronic disease
* Progressive weight loss
* Night sweats
* Chronic cough
* Hemoptysis
Mycobacterium tuberculosis
* Acid fast bacillus (AFB)
* Resistant to drying
* Aerobic, slow growth
* Airborne transmission
* Inhale airborne droplets
* Ingested by alveolar macrophages
* Multiply in macrophages even with ongoing immune response

TB Response
* Host immune response-delayed type hypersensitivity reaction
* Tissue damage DT Inflammatory response
TB Conversion
* TST skin reaction is positive
* Occurs within 24 – 48 hours after exposure to TB antigens
* Purified protein derivative of bacillus
* Cell mediated immunity
* Sensitized T cells react with proteins
QuantiferonGold
* Blood test
* Detects interferon gamma

How to Confirm Diagnosis
* Sputum cultures for AFB smear & culture
* Chest xray
Pathogenesis
* LTBI (latent TB infection)
Active Disease

* Low resistance

TB Outcomes
* Primary infection- positive skin test
* 10% progressive primary infection-not controlled
Secondary or Reactivation Infection
* Reinfection-2nd exposure or
* Bacteria escape immune system-reactivation
* Activated macrophages release cytokines
* Delayed hypersensitivity reaction

Prevention of Transmission
* Negative pressure rooms
* Respirator masks-fit tested
* Admit staff aware of symptoms of TB
* Yearly TST of staff
* Conversions treated with 6-9 months of INH

Treatment
* INH for LTBI or TB conversion
* TB disease-active TB
* 9- 12 months of treatment
Resistant TB
* MDR TB
* XDR TB
* DT improper treatment

BCG
* Live culture of M. bovis
Latent vs Active
* Latent TB
* Active TB
Leprosy
* Hanson’s disease- discovered in 1873
* Seen in tropics and underserved countries
* U.S.-150 new cases per year
* Infection of nervous system
* Infects the peripheral nerves within skin
* 2 forms of disease dependent upon immune response

M. leprae
* Tuberculoid form
Lepromatous Form
* Weak immune response & microbe spreads
* Skin & nerve cells infected
* Shed large #s in nasal secretions and oozing sores-more infectious
Invasion via Enzymes
Kinases
Enzymes
Invasion via Toxins
Exotoxins
A-B Toxins
Superantigens
Naming of Exotoxins
Endotoxin
S & S
Shock
Staphylococci
S. aureus
Successful Pathogen
Biofilm
Capsule
Skin Infections
Invasion via Toxins
Toxic shock syndrome
S. aureus Intoxication
Treatment
CA-MRSA
Outbreaks in Community
PVL Gene
Preventing Transmission
Clostridium botulinum
Neurotoxin
Botulism-Foodborne Disease
Toxin
Clostridium tetani
Neurotoxin
Lockjaw
Clostridium difficile
Epidemiology
Range of Disease
Pathogenesis of CDI
New Issues
Treatment
Transmission
Environment

* Clean and disinfect surfaces in close proximity of the patient
* Patient care equipment.
* Use bleach for C. difficile
* Privacy drapes

Bacteria Pathogenicity Ability to Cause Infection.ppt

Read more...
All links posted here are collected from various websites. No video or powerpoint files are uploaded on this blog. If you are the original author and do not wish to display your content on this blog please Email me anandkumarreddy at gmail dot com I will remove it. The contents of this blog are meant for educational purpose and not for commercial use. If you use any content give due credit to the original author.

This site uses cookies from Google to deliver its services, to personalise ads and to analyse traffic. Information about your use of this site is shared with Google. By using this site, you agree to its use of cookies.

  © Blogger templates Newspaper III by Ourblogtemplates.com 2008

Back to TOP